Small cell lung cancer (SCLC) is characterised by high relapse rates. Tumour-initiating cells (TICs) are responsible for drug resistance and recurrence of cancer. Rovalpituzumab tesirine (Rova-T), a potent humanised antibody–drug conjugate, selectively targets delta-like protein 3, which is highly expressed in SCLC TICs. The experimental drug CBL0137 (CBL) inhibits the histone chaperone FACT (facilitates chromatin transcription), which is required for the expression of transcription factors that are essential for TIC maintenance. Rova-T and CBL each target SCLC TICs as single agents. However, acquired or intrinsic resistance to single agents is a major problem in cancer. Therefore, we investigated the potential effect of combining Rova-T and CBL in SCLC to eradicate TICs more effectively. Our preclinical studies report a novel and highly translatable therapeutic strategy of dual targeting TICs using Rova-T in combination with CBL to potentially increase survival of SCLC patients.
Subscribe to Journal
Get full journal access for 1 year
only $4.96 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Codony-Servat, J., Verlicchi, A. & Rosell, R. Cancer stem cells in small cell lung cancer. Transl. Lung Cancer Res. 5, 16–25 (2016).
Wang, J., Li, Z. H., White, J. & Zhang, L. B. Lung cancer stem cells and implications for future therapeutics. Cell Biochem. Biophys. 69, 389–398 (2014).
Eramo, A., Haas, T. L. & De Maria, R. Lung cancer stem cells: tools and targets to fight lung cancer. Oncogene 29, 4625–4635 (2010).
MacDonagh, L., Gray, S. G., Breen, E., Cuffe, S., Finn, S. P., O’Byrne, K. J. et al. Lung cancer stem cells: the root of resistance. Cancer Lett. 372, 147–156 (2016).
Saunders, L. R., Bankovich, A. J., Anderson, W. C., Aujay, M. A., Bheddah, S., Black, K. et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci. Transl. Med. 7, 302ra136 (2015).
Gasparian, A. V., Burkhart, C. A., Purmal, A. A., Brodsky, L., Pal, M., Saranadasa, M. et al. Curaxins: anticancer compounds that simultaneously suppress NF-kappaB and activate p53 by targeting FACT. Sci. Transl. Med. 3, 95ra74 (2011).
Dermawan, J. K., Hitomi, M., Silver, D. J., Wu, Q., Sandlesh, P., Sloan, A. E. et al. Pharmacological targeting of the histone chaperone complex FACT preferentially eliminates glioblastoma stem cells and prolongs survival in preclinical models. Cancer Res. 76, 2432–2442 (2016).
De, S., Lindner, D. J., Coleman, C., Wildey, G., Dowlati, A., Stark, G. R. et al. The FACT inhibitor CBL0137 synergizes with cisplatin in small cell lung cancer by increasing NOTCH1 expression and targeting tumor-initiating cells. Cancer Res. 78, 2396–2406 (2018).
Kolev, V. N., Wright, Q. G., Vidal, C. M., Ring, J. E., Shapiro, I. M., Ricono, Jill, D. et al. PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells. Cancer Res. 75, 446–455 (2015).
Hu, Y. & Smyth, G. K. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J. Immunol. Methods 347, 70–78 (2009).
Sullivan, J. P., Spinola, M., Dodge, M., Raso, M. G., Behrens, C., Gao, B. et al. Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res. 70, 9937–9948 (2010).
Van Den Borg, R., Leonett, A., Tiseo, M., Giovannetti, E. & Peters, G. J. Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirine. Expert Rev. Anticancer Ther. 19, 461–471 (2019).
Morgensztern, D., Besse, B., Greillier, L., Davila, R. S., Ready, N., Christine, L. et al. Efficacy and safety of rovalpituzumab tesirine in third-line and beyond patients with DLL3-expressing, relapsed/refractory small-cell lung cancer: results from the Phase II TRINITY Study. Clin. Cancer Res. 25, 6958–6966 (2019).
We are extremely thankful to Drs. Andrei Gudkov and Andrei A. Purmal of Incuron Inc. for providing CBL0137. We would like to thank AbbVie Inc. for providing Rova-T, and Dr. Shawn Jeffries, the clinical director of AbbVie, for his support and scientific input. We appreciate the technical support of the Cleveland Clinic Flow Cytometry Core.
Ethics approval and consent to participate
All animal experiments were approved by the Cleveland Clinic Foundation Institutional Animal Care and Use Committee and conducted in accordance with the National Institute of Health (NIH) Guide for the Care and Use of Laboratory Animals (Protocol Number: 2017-1863). The cell lines used in this study were obtained from ATCC.
Consent to publish
All data generated or analysed during this study are included in this article and its supplementary information files.
The authors declare no competing interests.
This research was mainly supported by a Concept Grant (LC170491) from the US Department of Defense (DoD) to S.D. Studies were supported, in part, by the Case Comprehensive Cancer Center Athymic Animal and Xenograft Core and NCI core grant P30 CA043703-23.
Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Lindner, D.J., Wildey, G., Parker, Y. et al. CBL0137 increases the targeting efficacy of Rovalpituzumab tesirine against tumour-initiating cells in small cell lung cancer. Br J Cancer 124, 893–895 (2021). https://doi.org/10.1038/s41416-020-01192-x
Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma
Journal of Experimental & Clinical Cancer Research (2021)